Alere Inc (ALR) Quote| Reuters.com
Edition:
United States

Alere Inc (ALR)

ALR on New York Consolidated

41.25USD
28 Jun 2016
Change (% chg)

-- (--)
Prev Close
$41.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,409,651
52-wk High
$55.99
52-wk Low
$31.96

ALR

Chart for ALR

About

Alere Inc. is a provider of health information through diagnostic tests. The Company operates through professional diagnostics, patient self-testing, consumer diagnostics and, corporate and other segments. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests... (more)

Overall

Beta: 1.51
Market Cap(Mil.): $3,558.09
Shares Outstanding(Mil.): 86.26
Dividend: --
Yield (%): --

Financials

  ALR Industry Sector
P/E (TTM): -- 31.02 34.67
EPS (TTM): -0.42 -- --
ROI: -0.47 8.50 14.11
ROE: -2.51 12.81 15.33

BRIEF-Alere HIV assay awarded WHO prequalification, making it available for public sector procurement

* Alere q hiv-1/2 detect assay awarded world health organization (who) prequalification , making it available for public sector procurement Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jun 16 2016

BRIEF-Alere modifies consent solicitations for senior notes

* Alere Inc. Announces modifications of consent solicitations for Alere Inc.'s notes Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

May 05 2016

BRIEF-Moody's says Alere's receipt of lender approval for amendment is a positive development

* Alere's receipt of lender approval for amendment and waiver is a positive development; ratings unaffected Source text (http://bit.ly/1VYiBej) (Bengaluru Newsroom; +1 646 223 8780; )

Apr 29 2016

BRIEF-Alere announces commencement of consent solicitations for its notes

* Alere Inc. announces commencement of consent solicitations for Alere Inc.'s notes

Apr 29 2016

Alere says it rejected Abbott's request to end merger deal

Diagnostic test maker Alere Inc said its board has rejected a recent request by Abbott Laboratories Inc to terminate the $5.8 billion deal to buy Alere for a breakup fee.

Apr 29 2016

BRIEF-Alere obtains requisite lender approval for extension to file Form 10

* Announces certain developments relating to the pending merger transaction with abbott laboratories

Apr 28 2016

BRIEF-Abbott CEO says it was not in discussions with St Jude last summer

* Abbott CEO Miles White says on conference call that the company was not in discussions with St Jude last summer when "false" rumors surfaced in the media

Apr 28 2016

Alere receives default notice from bondholder group - Bloomberg

April 25 Alere Inc received a notice of default from a group of its bondholders after the diagnostics company delayed filing its 2015 annual report in March, Bloomberg reported Monday.

Apr 25 2016

BRIEF-Alere received notice of default from group of bondholders - Bloomberg

* Alere Inc received a notice of default from a group of bondholders after co delayed filing its 2015 financial statement - Bloomberg, citing sources Source text : (http://bloom.bg/1TtAPkC) Further company coverage:

Apr 25 2016

Diagnostics company Alere hit with securities fraud class action

NEW YORK Diagnostics company Alere Inc has been hit with a securities fraud lawsuit accusing it of artificially inflating its share prices ahead of the Feb. 1 announcement of its proposed $5.8 billion acquisition by Abbott Laboratories Inc.

Apr 22 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.